Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer’s disease and down syndrome

BACKGROUND: There is still a substantial unmet need for less invasive and lower-cost blood-based biomarkers to detect brain Alzheimer’s disease (AD) pathology. This study is aimed to determine whether quantification of plasma tau phosphorylated at threonine 181 (p-tau181) is informative in the diagn...

Descripción completa

Detalles Bibliográficos
Autores principales: Tatebe, Harutsugu, Kasai, Takashi, Ohmichi, Takuma, Kishi, Yusuke, Kakeya, Tomoshi, Waragai, Masaaki, Kondo, Masaki, Allsop, David, Tokuda, Takahiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582385/
https://www.ncbi.nlm.nih.gov/pubmed/28866979
http://dx.doi.org/10.1186/s13024-017-0206-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582385/
https://www.ncbi.nlm.nih.gov/pubmed/28866979
http://dx.doi.org/10.1186/s13024-017-0206-8

Ejemplares similares